{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:23Z","timestamp":1792173443118,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Co. Ltd.","award":["Takeda (China) International Trading Co. Ltd."],"award-info":[{"award-number":["Takeda (China) International Trading Co. Ltd."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hereditary angioedema (HAE) is a rare autosomal dominant genetic disease characterized by repetitive subcutaneous or submucosal angioedema, activation of the kinin system, and increased vascular permeability. C1-inhibitor (C1-INH) deficiency, the main mechanism of HAE pathogenesis, occurs when abnormal activation of plasma kallikrein, bradykinin, and factor XII, or mutation of genes such as <jats:italic>SERPING1<\/jats:italic> cause quantitative or functional C1-INH defects. Although androgens are not approved for HAE treatment in many countries, they are widely used in China and Brazil to reduce the frequency and severity of HAE attacks. The long-term adverse effects of androgen treatment are concerning for both physicians and patients. Virilization, weight gain, acne, hirsutism, liver damage, headache, myalgia, hematuria, menstrual disorders, diminished libido, arterial hypertension, dyslipidemia, and anxiety\/depression are commonly observed during long-term treatment with androgens. These adverse effects can affect the quality of life of HAE patients and often lead to treatment interruption, especially in women and children. In-depth studies of the pathogenesis of HAE have led to the approval of alternative treatment strategies, including plasma-derived C1 inhibitor, recombinant human C1 inhibitor, plasma Kallikrein inhibitor (ecallantide; lanadelumab), and bradykinin B2 receptor antagonist (icatibant), some of which have achieved satisfactory results with mostly non-serious side effects. Therefore, a new standard of medical care may expand possibilities for the management of HAE in emerging countries.<\/jats:p>","DOI":"10.1186\/s13023-022-02536-x","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T13:03:12Z","timestamp":1667394192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries"],"prefix":"10.1186","volume":"17","author":[{"given":"Yinshi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herberto J.","family":"Chong-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange O. R.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-3381","authenticated-orcid":false,"given":"Rongfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2536_CR1","doi-asserted-by":"publisher","unstructured":"Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114(4). https:\/\/doi.org\/10.1016\/j.anai.2015.01.003.","DOI":"10.1016\/j.anai.2015.01.003"},{"issue":"2","key":"2536_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1684\/ejd.2020.3758","volume":"30","author":"S Liu","year":"2020","unstructured":"Liu S, Xu Q, Xu Y, Wang X, Zhi Y. Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey. Eur J Dermatol. 2020;30(2):169\u201376. https:\/\/doi.org\/10.1684\/ejd.2020.3758.","journal-title":"Eur J Dermatol"},{"key":"2536_CR3","doi-asserted-by":"publisher","unstructured":"Santacroce R, D\u2019Andrea G, Maffione AB, Margaglione M, d\u2019Apolito M. The Genetics of Hereditary Angioedema: A Review. J Clin Med. 2021;10(9). https:\/\/doi.org\/10.3390\/jcm10092023.","DOI":"10.3390\/jcm10092023"},{"key":"2536_CR4","doi-asserted-by":"publisher","unstructured":"Johnston DT, Henry Li H, Craig TJ, Bernstein JA, Anderson J, Joseph K, et al. Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. Allergy Asthma Proc. 2021;42(1):22 \u2013 9. https:\/\/doi.org\/10.2500\/aap.2021.42.200106.","DOI":"10.2500\/aap.2021.42.200106"},{"key":"2536_CR5","doi-asserted-by":"publisher","unstructured":"Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001 Nov 12;161(20):2417-29. https:\/\/doi.org\/10.1001\/archinte.161.20.2417.","DOI":"10.1001\/archinte.161.20.2417"},{"issue":"12","key":"2536_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"PJ Busse","year":"2020","unstructured":"Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med. 2020;382(12):1136\u201348. https:\/\/doi.org\/10.1056\/NEJMra1808012.","journal-title":"N Engl J Med"},{"key":"2536_CR7","doi-asserted-by":"publisher","unstructured":"Patel G, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc. 2019;40(6):441-5. https:\/\/doi.org\/10.2500\/aap.2019.40.4267.","DOI":"10.2500\/aap.2019.40.4267"},{"key":"2536_CR8","doi-asserted-by":"publisher","unstructured":"Veronez CL, Mendes AR, Leite CS, Gomes CP, Grumach AS, Pesquero JB. The Panorama of Primary Angioedema in the Brazilian Population. J Allergy Clin Immunol Pract. 2021;9(6). https:\/\/doi.org\/10.1016\/j.jaip.2020.11.039.","DOI":"10.1016\/j.jaip.2020.11.039"},{"issue":"1","key":"2536_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1684\/ejd.2018.3487","volume":"29","author":"S Liu","year":"2019","unstructured":"Liu S, Xu Y, Liu Y, Zhi Y. Hereditary angioedema: a Chinese perspective. Eur J Dermatol. 2019;29(1):14\u201320. https:\/\/doi.org\/10.1684\/ejd.2018.3487.","journal-title":"Eur J Dermatol"},{"issue":"9","key":"2536_CR10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1590\/s1807-59322011000900021","volume":"66","author":"P Giavina-Bianchi","year":"2011","unstructured":"Giavina-Bianchi P, Franca AT, Grumach AS, Motta AA, Fernandes FR, Campos RA, et al. Brazilian guidelines for the diagnosis and treatment of hereditary angioedema. Clin (Sao Paulo). 2011;66(9):1627\u201336. https:\/\/doi.org\/10.1590\/s1807-59322011000900021.","journal-title":"Clin (Sao Paulo)"},{"key":"2536_CR11","doi-asserted-by":"publisher","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1). https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046.","DOI":"10.1016\/j.jaip.2020.08.046"},{"issue":"4","key":"2536_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/07853890.2016.1162909","volume":"48","author":"S Zeerleder","year":"2016","unstructured":"Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;48(4):256\u201367. https:\/\/doi.org\/10.3109\/07853890.2016.1162909.","journal-title":"Ann Med"},{"issue":"3","key":"2536_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0165-2478(03)00029-4","volume":"86","author":"E Pappalardo","year":"2003","unstructured":"Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett. 2003;86(3):271\u20136. https:\/\/doi.org\/10.1016\/s0165-2478(03)00029-4.","journal-title":"Immunol Lett"},{"issue":"2","key":"2536_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0165-2478(03)00029-4","volume":"121","author":"C Drouet","year":"2008","unstructured":"Drouet C, D\u00e9sormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429\u201333. https:\/\/doi.org\/10.1016\/s0165-2478(03)00029-4.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2536_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/16078454.2020.1815129","volume":"25","author":"Q Gao","year":"2020","unstructured":"Gao Q, Zhang L, Zhao X, Zhu Y, Peng G, Li Y, et al. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia. Hematology. 2020;25(1):341\u20137. https:\/\/doi.org\/10.1080\/16078454.2020.1815129.","journal-title":"Hematology"},{"issue":"Supplement","key":"2536_CR16","doi-asserted-by":"publisher","first-page":"60-S8","DOI":"10.4103\/0973-1482.181175","volume":"15","author":"J Qin","year":"2019","unstructured":"Qin J, Cui N, Hou R, Liu T, Sun H, Liu Y, et al. Association between androgen receptor gene polymorphisms and testicular germ cell tumor: A systematic review and meta-analysis. J Cancer Res Ther. 2019;15(Supplement):60-S8. https:\/\/doi.org\/10.4103\/0973-1482.181175.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"2536_CR17","doi-asserted-by":"publisher","first-page":"155798832092244","DOI":"10.1177\/1557988320922443","volume":"14","author":"RA Rey","year":"2020","unstructured":"Rey RA, Grinspon RP. Androgen Treatment in Adolescent Males With Hypogonadism. Am J Mens Health. 2020;14(3):1557988320922443. https:\/\/doi.org\/10.1177\/1557988320922443.","journal-title":"Am J Mens Health"},{"issue":"3","key":"2536_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/0003-4819-86-3-306","volume":"86","author":"AL Sheffer","year":"1977","unstructured":"Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med. 1977;86(3):306\u20138. https:\/\/doi.org\/10.7326\/0003-4819-86-3-306.","journal-title":"Ann Intern Med"},{"key":"2536_CR19","doi-asserted-by":"crossref","unstructured":"Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295(26):1444-8. http:\/\/dx.doi.org\/23;295(26): 1444-8.","DOI":"10.1056\/NEJM197612232952602"},{"issue":"2","key":"2536_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","volume":"100","author":"K Bork","year":"2008","unstructured":"Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153\u201361. https:\/\/doi.org\/10.1016\/S1081-1206(10)60424-3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2536_CR21","doi-asserted-by":"publisher","unstructured":"Zuraw BL, Davis DK, Castaldo AJ, Christiansen SC. Tolerability and Effectiveness of 17-\u03b1-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination. J Allergy Clin Immunol Pract. 2016;4(5). https:\/\/doi.org\/10.1016\/j.jaip.2016.03.024.","DOI":"10.1016\/j.jaip.2016.03.024"},{"issue":"3","key":"2536_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cei.12584","volume":"180","author":"HJ Longhurst","year":"2015","unstructured":"Longhurst HJ, Tarzi MD, Ashworth F, Bethune C, Cale C, Dempster J, et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol. 2015;180(3):475\u201383. https:\/\/doi.org\/10.1111\/cei.12584.","journal-title":"Clin Exp Immunol"},{"key":"2536_CR23","doi-asserted-by":"publisher","unstructured":"Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges. 2011;9(2). https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07546.x.","DOI":"10.1111\/j.1610-0387.2010.07546.x"},{"key":"2536_CR24","doi-asserted-by":"publisher","unstructured":"Cao Y, Liu S, Zhi Y. Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema. Allergy Asthma Proc. 2021;42(2):131-5. https:\/\/doi.org\/10.2500\/aap.2021.42.210001.","DOI":"10.2500\/aap.2021.42.210001"},{"key":"2536_CR25","doi-asserted-by":"publisher","unstructured":"Tse KY, Zuraw BL, Chen Q, Christiansen SC. Anabolic androgen use in the management of hereditary angioedema: Not so cheap after all. Ann Allergy Asthma Immunol. 2017;118(4). https:\/\/doi.org\/10.1016\/j.anai.2017.01.015.","DOI":"10.1016\/j.anai.2017.01.015"},{"key":"2536_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13023-014-0205-6","volume":"9","author":"Z Zotter","year":"2014","unstructured":"Zotter Z, Veszeli N, Csuka D, et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet J Rare Dis. 2014;9:205. https:\/\/doi.org\/10.1186\/s13023-014-0205-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2536_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ajog.2008.04.034","volume":"199","author":"L Bouillet","year":"2008","unstructured":"Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1-.e4. https:\/\/doi.org\/10.1016\/j.ajog.2008.04.034.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2536_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaci.2011.11.025","volume":"129","author":"T Caballero","year":"2012","unstructured":"Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308\u201320. https:\/\/doi.org\/10.1016\/j.jaci.2011.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2536_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0091-6749(81)90181-0","volume":"68","author":"AL Sheffer","year":"1981","unstructured":"Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981;68(3):181\u20137. https:\/\/doi.org\/10.1016\/0091-6749(81)90181-0.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2536_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0015-0282(16)53638-3","volume":"54","author":"JJ Zurlo","year":"1990","unstructured":"Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril. 1990;54(1):64\u201372. https:\/\/doi.org\/10.1016\/s0015-0282(16)53638-3.","journal-title":"Fertil Steril"},{"issue":"6","key":"2536_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1055\/s-2008-1064982","volume":"93","author":"SW Hosea","year":"1980","unstructured":"Hosea SW, Santaella ML, Brown EJ, et al. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med. 1980;93(6):809\u201312. https:\/\/doi.org\/10.1055\/s-2008-1064982.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2536_CR32","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaad.2018.08.062","volume":"80","author":"A Bienenfeld","year":"2019","unstructured":"Bienenfeld A, Azarchi S, Lo Sicco K, et al. Androgens in women: Androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497\u2013506. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.062.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2536_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/09513590802454943","volume":"24","author":"S Lello","year":"2008","unstructured":"Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3\u00a0mg and ethynilestradiol 30 microg and chlormadinone 2\u00a0mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol. 2008;24(12):718\u201323. https:\/\/doi.org\/10.1080\/09513590802454943.","journal-title":"Gynecol Endocrinol"},{"issue":"12","key":"2536_CR34","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1210\/jc.2003-030562","volume":"88","author":"S Elsenbruch","year":"2003","unstructured":"Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(12):5801\u20137. https:\/\/doi.org\/10.1210\/jc.2003-030562.","journal-title":"J Clin Endocrinol Metab"},{"key":"2536_CR35","doi-asserted-by":"crossref","unstructured":"Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet. 1977;2(8032):262-3. http:\/\/dx.doi.org\/6;2(8032): 262-3.","DOI":"10.1016\/S0140-6736(77)90949-7"},{"issue":"6","key":"2536_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/oxfordjournals.humrep.a138651","volume":"9","author":"J Balasch","year":"1994","unstructured":"Balasch J, Martinez-Rom\u00e1n S, Carreras J, et al. Acute pancreatitis associated with danazol treatment for endometriosis. Hum Reprod. 1994;9(6):1163\u20135. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a138651.","journal-title":"Hum Reprod"},{"issue":"5","key":"2536_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/s0168-8278(02)00035-1","volume":"36","author":"K Bork","year":"2002","unstructured":"Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol. 2002;36(5):707\u20139. https:\/\/doi.org\/10.1016\/s0168-8278(02)00035-1.","journal-title":"J Hepatol"},{"issue":"3","key":"2536_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/0091-6749(83)90034-9","volume":"72","author":"M Cicardi","year":"1983","unstructured":"Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol. 1983;72(3):294\u20138. https:\/\/doi.org\/10.1016\/0091-6749(83)90034-9.","journal-title":"J Allergy Clin Immunol"},{"key":"2536_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1196\/annals.1386.044","volume":"1089","author":"L Giannitrapani","year":"2006","unstructured":"Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci. 2006;1089:228\u201336. https:\/\/doi.org\/10.1196\/annals.1386.044.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2536_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2340\/00015555-0057","volume":"86","author":"P Helsing","year":"2006","unstructured":"Helsing P, Nielsen EW. Hepatocellular focal nodular hyperplasia after danazol treatment for hereditary angio-oedema. Acta Derm Venereol. 2006;86(3):272\u20133. https:\/\/doi.org\/10.2340\/00015555-0057.","journal-title":"Acta Derm Venereol"},{"key":"2536_CR41","doi-asserted-by":"publisher","unstructured":"Corfield EC, Martin NG, Nyholt DR. Co-occurrence and symptomatology of fatigue and depression. Compr Psychiatry 2016;71. https:\/\/doi.org\/10.1016\/j.comppsych.2016.08.004.","DOI":"10.1016\/j.comppsych.2016.08.004"},{"issue":"1","key":"2536_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0022-5347(17)45509-1","volume":"135","author":"GL Andriole","year":"1986","unstructured":"Andriole GL, Brickman C, Lack EE, et al. Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. J Urol. 1986;135(1):44\u20136. https:\/\/doi.org\/10.1016\/s0022-5347(17)45509-1.","journal-title":"J Urol"},{"issue":"4","key":"2536_CR43","first-page":"248","volume":"38","author":"AM Rosado-Qui\u00f1ones","year":"2019","unstructured":"Rosado-Qui\u00f1ones AM, Zaragoza-Urdaz R. Hereditary Angioedema: An Updated Experience with Patients with Angioedema in Puerto Rico. P R Health Sci J. 2019;38(4):248\u201354. http:\/\/dx.doi.org\/38. 4 : 248\u2013254.","journal-title":"P R Health Sci J"},{"issue":"12","key":"2536_CR44","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","volume":"30","author":"RS Birjmohun","year":"2008","unstructured":"Birjmohun RS, Kees Hovingh G, Stroes ESG, et al. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther. 2008;30(12):2314\u201323. https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.021.","journal-title":"Clin Ther"},{"issue":"4","key":"2536_CR45","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaci.2004.12.1130","volume":"115","author":"G Sz\u00e9plaki","year":"2005","unstructured":"Sz\u00e9plaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol. 2005;115(4):864\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2004.12.1130.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2536_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00007256-200434080-00003","volume":"34","author":"F Hartgens","year":"2004","unstructured":"Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513\u201354. https:\/\/doi.org\/10.2165\/00007256-200434080-00003.","journal-title":"Sports Med"},{"issue":"1","key":"2536_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.yrtph.2010.02.001","volume":"57","author":"J van Amsterdam","year":"2010","unstructured":"van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117\u201323. https:\/\/doi.org\/10.1016\/j.yrtph.2010.02.001.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"2536_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.amjcard.2010.05.013","volume":"106","author":"S Achar","year":"2010","unstructured":"Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893\u2013901. https:\/\/doi.org\/10.1016\/j.amjcard.2010.05.013.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2536_CR49","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archinte.140.10.1379","volume":"140","author":"JA Bretza","year":"1980","unstructured":"Bretza JA, Novey HS, Vaziri ND, et al. Hypertension: a complication of danazol therapy. Arch Intern Med. 1980;140(10):1379\u201380. https:\/\/doi.org\/10.1001\/archinte.140.10.1379.","journal-title":"Arch Intern Med"},{"issue":"6583","key":"2536_CR50","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/bmj.294.6583.1323","volume":"294","author":"A Shah","year":"1987","unstructured":"Shah A, Roberts T, McQueen IN, et al. Danazol and benign intracranial hypertension. Br Med J (Clin Res Ed). 1987;294(6583):1323. https:\/\/doi.org\/10.1136\/bmj.294.6583.1323.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5","key":"2536_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","volume":"1","author":"BL Zuraw","year":"2013","unstructured":"Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458\u201367. https:\/\/doi.org\/10.1016\/j.jaip.2013.07.002.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2536_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13256-020-02622-3","volume":"15","author":"\u017d Kardum","year":"2021","unstructured":"Kardum \u017d, Prus V, Milas Ahi\u0107 J, et al. Successful treatment with Cinryze\u00ae replacement therapy of a pregnant patient with hereditary angioedema: a case report. J Med Case Rep. 2021;15(1):20. https:\/\/doi.org\/10.1186\/s13256-020-02622-3.","journal-title":"J Med Case Rep"},{"issue":"8","key":"2536_CR53","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/pm\/pnaa457","volume":"22","author":"KJ Clark","year":"2021","unstructured":"Clark KJ, Sviggum HP, Jacob AK, et al. Obstetric Anesthetic Management for Parturients with Hereditary Angioedema: A Case Report and Suggested Protocol. Pain Med. 2021;22(8):1878\u201382. https:\/\/doi.org\/10.1093\/pm\/pnaa457.","journal-title":"Pain Med"},{"issue":"15","key":"2536_CR54","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s40265-018-0987-2","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Lanadelumab. First Global Approval. Drugs. 2018;78(15):1633\u20137. https:\/\/doi.org\/10.1007\/s40265-018-0987-2.","journal-title":"Drugs"},{"issue":"1","key":"2536_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaci.2021.05.023","volume":"148","author":"LK Arruda","year":"2021","unstructured":"Arruda LK, Ferriani MPL. Treatment of hereditary angioedema: When the goal is having a normal life. J Allergy Clin Immunol. 2021;148(1):80\u20132. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2536_CR56","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaip.2015.12.010","volume":"4","author":"N Prior","year":"2016","unstructured":"Prior N, Remor E, Perez-Fernandez E, et al. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4(3):464\u201373. https:\/\/doi.org\/10.1016\/j.jaip.2015.12.010. e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2536_CR57","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","volume":"119","author":"K Bork","year":"2006","unstructured":"Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267\u201374. https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.064.","journal-title":"Am J Med"},{"issue":"5","key":"2536_CR58","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archinte.161.5.714","volume":"161","author":"K Bork","year":"2001","unstructured":"Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161(5):714\u20138. https:\/\/doi.org\/10.1001\/archinte.161.5.714.","journal-title":"Arch Intern Med"},{"key":"2536_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.016","author":"M Maurer","year":"2021","unstructured":"Maurer M, Aygoren-Pursun E, Banerji A, et al. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.016.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2536_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-019-1159-5","volume":"14","author":"S Liu","year":"2019","unstructured":"Liu S, Wang X, Xu Y, et al. Health-related quality of life and its risk factors in Chinese hereditary angioedema patients. Orphanet J Rare Dis. 2019;14(1):191. https:\/\/doi.org\/10.1186\/s13023-019-1159-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2536_CR61","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1111\/j.1537-2995.2009.02230.x","volume":"49","author":"W Kreuz","year":"2009","unstructured":"Kreuz W, Martinez-Saguer I, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion. 2009;49(9):1987\u201395. https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02230.x.","journal-title":"Transfusion"},{"key":"2536_CR62","doi-asserted-by":"publisher","unstructured":"Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, et al. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. J Allergy Clin Immunol Pract. 2019;7(6). https:\/\/doi.org\/10.1016\/j.jaip.2019.01.054.","DOI":"10.1016\/j.jaip.2019.01.054"},{"issue":"1","key":"2536_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18176\/jiaci.0653","volume":"31","author":"T Caballero","year":"2021","unstructured":"Caballero T. Treatment of Hereditary Angioedema. J Investig Allergol Clin Immunol. 2021;31(1):1\u201316.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"8","key":"2536_CR64","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2217\/imt-2017-0049","volume":"10","author":"R Gupta","year":"2018","unstructured":"Gupta R, Balduzzi J, Davis-Lorton M. C1-esterase inhibitor (Cinryze) use in the treatment of pediatric hereditary angioedema. Immunotherapy. 2018;10(8):635\u201342. https:\/\/doi.org\/10.2217\/imt-2017-0049.","journal-title":"Immunotherapy"},{"issue":"20","key":"2536_CR65","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018;320(20):2108\u201321. https:\/\/doi.org\/10.1001\/jama.2018.16773.","journal-title":"JAMA"},{"issue":"6","key":"2536_CR66","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.jaip.2021.01.040","volume":"9","author":"A Belb\u00e9zier","year":"2021","unstructured":"Belb\u00e9zier A, Boccon-Gibod I, Bouillet L. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2021;9(6):2490\u20131. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.040.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2536_CR67","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14680","volume":"76","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Weller K, Magerl M, Banerji A, Longhurst HJ, Riedl MA, et al. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2021;76(4):1188\u201398. https:\/\/doi.org\/10.1111\/all.14680.","journal-title":"Allergy"},{"issue":"3","key":"2536_CR68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-021-01475-4","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A, Berotralstat. First Approval Drugs. 2021;81(3):405\u20139. https:\/\/doi.org\/10.1007\/s40265-021-01475-4.","journal-title":"First Approval Drugs"},{"key":"2536_CR69","doi-asserted-by":"publisher","unstructured":"Zuraw B, Lumry WR, Johnston DT, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Banerji A, Bernstein JA, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1). https:\/\/doi.org\/10.1016\/j.jaci.2020.10.015.","DOI":"10.1016\/j.jaci.2020.10.015"},{"issue":"10328","key":"2536_CR70","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","volume":"399","author":"T Craig","year":"2022","unstructured":"Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399(10328):945\u201355.","journal-title":"Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02536-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T13:08:49Z","timestamp":1667394529000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2536"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02536-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}